for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jazz Pharmaceuticals PLC

JAZZ.OQ

Latest Trade

151.05USD

Change

-0.54(-0.36%)

Volume

162,319

Today's Range

150.72

 - 

153.03

52 Week Range

116.56

 - 

154.10

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Pharmamar & Jazz Pharmaceuticals Sign Exclusive License Agreement For Lurbinectedin

Dec 19 (Reuters) - Jazz Pharmaceuticals PLC <JAZZ.O>::PHARMAMAR AND JAZZ PHARMACEUTICALS SIGN EXCLUSIVE LICENSE AGREEMENT FOR LURBINECTEDIN IN THE U.S..JAZZ PHARMACEUTICALS PLC - JAZZ TO PAY AN UPFRONT PAYMENT OF $200 MILLION TO PHARMAMAR.JAZZ PHARMACEUTICALS PLC - PHARMAMAR IS ALSO ELIGIBLE TO RECEIVE UP TO $800 MILLION IN POTENTIAL MILESTONE PAYMENTS IN ADDITION TO ROYALTIES ON NET SALES.JAZZ PHARMACEUTICALS PLC - LURBINECTEDIN NDA SUBMITTED TO FDA IN DECEMBER 2019 WITH POTENTIAL TO LAUNCH IN 2020.JAZZ PHARMACEUTICALS PLC - PHARMAMAR & JAZZ PHARMACEUTICALS IRELAND LIMITED HAVE ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT FOR LURBINECTEDIN IN U.S..JAZZ PHARMACEUTICALS PLC - PHARMAMAR RETAINS PRODUCTION RIGHTS FOR LURBINECTEDIN AND WILL SUPPLY PRODUCT TO CO.JAZZ PHARMACEUTICALS PLC - PHARMAMAR IS ALSO ELIGIBLE TO RECEIVE UP TO $550 MILLION IN POTENTIAL COMMERCIAL MILESTONE PAYMENTS UNDER AGREEMENT.

PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement For Lurbinectedin In U.S.

Dec 19 (Reuters) - Pharma Mar SA <PHMR.MC>::ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH JAZZ PHARMACEUTICALS TO COMMERCIALIZE LURBINECTEDIN IN THE UNITED STATES.TO GET UP-FRONT PAYMENT OF $200 MLN, WITH POTENTIAL REGULATORY MILESTONE PAYMENTS OF UP TO $250 MLN UPON ACHIEVEMENT OF ACCELERATED AND/OR FULL REGULATORY APPROVAL.IS ELIGIBLE TO RECEIVE UP TO 550 MLN DOLLARS IN POTENTIAL COMMERCIAL MILESTONE PAYMENTS AS WELL AS INCREMENTAL TIERED ROYALTIES ON FUTURE NET SALES.RETAINS PRODUCTION RIGHTS FOR LURBINECTEDIN AND WILL SUPPLY THE PRODUCT TO JAZZ.

Jazz Pharmaceuticals Receives Positive CHMP Opinion For Solriamfetol To Improve Wakefulness And Reduce Excessive Daytime Sleepiness In Adults With Narcolepsy Or Obstructive Sleep Apnea

Nov 15 (Reuters) - Jazz Pharmaceuticals PLC <JAZZ.O>::JAZZ PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SOLRIAMFETOL TO IMPROVE WAKEFULNESS AND REDUCE EXCESSIVE DAYTIME SLEEPINESS IN ADULTS WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA.JAZZ PHARMACEUTICALS PLC - DECISION FROM EC ON SOLRIAMFETOL IS EXPECTED WITHIN 67 DAYS OF RECEIVING CHMP OPINION.

Jazz Pharmaceuticals Reports Q3 Earnings Per Share $1.78

Nov 5 (Reuters) - Jazz Pharmaceuticals PLC <JAZZ.O>::JAZZ PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $4.10.Q3 GAAP EARNINGS PER SHARE $1.78.SEES FY 2019 REVENUE UP 11 TO 15 PERCENT.SEES FY 2019 REVENUE $2.1 BILLION TO $2.18 BILLION.Q3 REVENUE $538 MILLION VERSUS REFINITIV IBES ESTIMATE OF $524.4 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $3.60 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $2.11 BILLION -- REFINITIV IBES DATA.2019 EPS GUIDANCE UPDATED TO $8.00-$9.00 ON A GAAP BASIS.2019 EPS GUIDANCE INCREASED TO $15.50-$16.15 ON AN ADJUSTED BASIS.FY2019 EARNINGS PER SHARE VIEW $15.03 -- REFINITIV IBES DATA.

Jazz Pharma Says CFO Matthew Young To Resign, Effective Oct 25, 2019

Oct 7 (Reuters) - Jazz Pharmaceuticals PLC <JAZZ.O>::JAZZ PHARMACEUTICALS - MATTHEW YOUNG HAS NOTIFIED CO OF HIS DECISION TO RESIGN FROM HIS POSITION AS CFO, EFFECTIVE AS OF OCTOBER 25, 2019.JAZZ PHARMACEUTICALS - BRUCE COZADD WILL ASSUME THE DUTIES AND RESPONSIBILITIES OF THE CO’S PRINCIPAL FINANCIAL OFFICER ON AN INTERIM BASIS.JAZZ PHARMACEUTICALS - EXPECTS YOUNG WILL CONTINUE AS CONSULTANT TO CO AND WITH TRANSITION OF HIS DUTIES AND RESPONSIBILITIES.

Jazz Pharmaceuticals PLC - QTRLY GAAP Diluted EPS Of $4.56 Adjusted Diluted EPS Of $4.05

Jazz Pharmaceuticals PLC <JAZZ.O>::JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.QTRLY TOTAL REVENUES INCREASED 7% TO $534 MILLION.QTRLY GAAP DILUTED EPS OF $4.56; ADJUSTED DILUTED EPS OF $4.05.SEES 2019 REVENUES $2,070 MILLION - $2,150 MILLION.SEES 2019 TOTAL NET PRODUCT SALES $2,055 MILLION - $2,125 MILLION.SEES 2019 GAAP NET INCOME PER DILUTED SHARE $9.40 - $10.75.SEES 2019 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $14.30 - $15.00.FY2019 EARNINGS PER SHARE VIEW $14.81, REVENUE VIEW $2.09 BILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $3.57, REVENUE VIEW $508.6 MILLION -- REFINITIV IBES DATA.

Jazz Pharmaceuticals Buys Pan-RAF Inhibitor Program From Redx

July 10 (Reuters) - Jazz Pharmaceuticals PLC <JAZZ.O>::JAZZ PHARMACEUTICALS ACQUIRES PRE-CLINICAL PAN-RAF INHIBITOR PROGRAM FROM REDX PHARMA.JAZZ PHARMACEUTICALS PLC - REDX TO RECEIVE $3.5 MILLION UPFRONT, UP TO $203 MILLION IN MILESTONE PAYMENTS AND ROYALTIES ON FUTURE NET SALES.JAZZ PHARMACEUTICALS PLC - REDX WILL PERFORM CERTAIN PRE-CLINICAL ACTIVITIES FOR PROGRAM UNDER A SEPARATE COLLABORATION AGREEMENT WITH JAZZ.JAZZ PHARMACEUTICALS PLC - JAZZ WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT, REGULATORY ACTIVITIES AND COMMERCIALIZATION.

Jazz Pharmaceuticals Acquires Pre-Clinical Pan-RAF Inhibitor Program From Redx Pharma

July 10 (Reuters) - Jazz Pharmaceuticals Plc <JAZZ.O>::JAZZ PHARMACEUTICALS ACQUIRES PRE-CLINICAL PAN-RAF INHIBITOR PROGRAM FROM REDX PHARMA.JAZZ WILL PAY REDX AN UPFRONT PAYMENT OF $3.5 MILLION.REDX TO RECEIVE UP TO $203 MILLION IN MILESTONE PAYMENTS AND ROYALTIES ON FUTURE NET SALES.REDX WILL PERFORM CERTAIN PRE-CLINICAL ACTIVITIES FOR PROGRAM UNDER A SEPARATE COLLABORATION AGREEMENT WITH JAZZ.

Jazz Pharmaceuticals Q1 GAAP Earnings Per Share $1.47

May 7 (Reuters) - Jazz Pharmaceuticals PLC <JAZZ.O>::JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $3.67.Q1 GAAP EARNINGS PER SHARE $1.47.Q1 EARNINGS PER SHARE ESTIMATE $3.16 -- REFINITIV IBES DATA.Q1 REVENUE $508 MILLION VERSUS REFINITIV IBES ESTIMATE OF $466 MILLION.REAFFIRMED 2019 FINANCIAL GUIDANCE..

Jazz Pharma Says Entered Into Corporate Integrity Agreement With OIG

April 4 (Reuters) - Jazz Pharmaceuticals PLC <JAZZ.O>::JAZZ PHARMACEUTICALS PLC - DURING 2018, RECORDED $58.2 MILLION RELATED TO CIVIL SETTLEMENT AGREEMENT WITH U.S. DOJ.JAZZ PHARMACEUTICALS PLC - IN CONNECTION WITH CIVIL SETTLEMENT, COMPANY ALSO ENTERED INTO A CORPORATE INTEGRITY AGREEMENT WITH OIG.JAZZ PHARMA - CORPORATE INTEGRITY AGREEMENT REQUIRES CO TO IMPOSE CERTAIN OVERSIGHT OBLIGATIONS ON NOMINATING & CORPORATE GOVERNANCE COMMITTEE OF BOARD.JAZZ PHARMACEUTICALS PLC - AGREEMENT WITH OIG REQUIRES COMPANY TO IMPLEMENT SET OF DEFINED CORPORATE INTEGRITY ACTIVITIES FOR A PERIOD OF FIVE YEARS.JAZZ PHARMACEUTICALS - CORPORATE INTEGRITY AGREEMENT ALSO INCLUDES CERTAIN REPORTING, CERTIFICATION, RECORD RETENTION, AND NOTIFICATION REQUIREMENTS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up